医学
中性粒细胞减少症
重症监护医学
美罗华
低丙种球蛋白血症
弥漫性血管内凝血
免疫学
抗体
化疗
内科学
作者
Luiz Henrique de Assis,Daniel El Fassi,Martin Hutchings
出处
期刊:Hematology
[American Society of Hematology]
日期:2023-12-08
卷期号:2023 (1): 216-222
被引量:2
标识
DOI:10.1182/hematology.2023000508
摘要
Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles. The hematological toxicities are common and potentially harmful, and the side effects have hitherto not been reviewed. With many BsAbs recently approved and entering routine clinical use, we have reviewed the rather limited published data and propose recommendations on the management of these toxicities. Our review of the available data confirms that hematological toxicities are among the most common toxicities, with potentially harmful consequences for the patients. Fortunately, hemophagocytic lymphohystiocytosis and disseminated intravascular coagulation are rare. Severe neutropenia and hypogammaglobulinemia are manageable, and their timely treatment and prevention may reduce morbidity and mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI